AVO | Our History

2021

Lessor financing partnership with DiaMedCare; selected as preferred supplier of leasing financing to customers in Europe and the US; opportunity for DiaMedCare to bridge manufacturing costs until delivery of the LIGHT system to customers
Infrastructure in place to support assembly and testing activities; system now capable of supporting the delivery of a proton pulse every 5 milliseconds; full medical software suite integrated; successful re-certification of ISO 13485
Equity fundraise of £6 million

2020

Business development:
- The London Clinic selected as the operator of the Proton Centre in Harley Street, London; Advanced Oncotherapy to receive a share of the profit of the Harley Street centre in London
- The London Clinic partners with the Cleveland Clinic in London; cancer patients to be referred to the proton therapy centre in Harley Street
- Sale of a LIGHT system to the Mediterranean Hospital of Limassol in Cyprus; Company to receive €50m and share of profits from clinical services
- Installation of a LIGHT system in collaboration with UHB on the UHB campus in Birmingham; revenue sharing arrangement to be implemented
Technical updates:
- Manufacturing of all critical hardware for first full-energy LIGHT system completed
- Site preparation at Daresbury ready to support the ultra-high vacuum tests and the high-voltage conditioning of the accelerating structures
- Machine installation process optimised enabling the reduction of the start-up time for future LIGHT systems
- First series of the magnets steering the beam towards the treatment room delivered
R&D partnerships:
- LIGHT Treatment plan System software installed at the Cleveland Clinic
- R&D Collaboration with University Hospitals Birmingham (UHB) NHS Foundation Trust
Funding:
- Two equity rounds of £23 million in total
- €20 million funding partnership with VDL Groep
- $30 million debt facility from Nerano Pharma
Corporate Governance:
- Mrs Lori Cross was appointed Non-Executive Director on the Board
- The Company held its first web-based Investor Day

2019

AVO在2019年第一季度获取了ISO:13485认证
2019年我们完成了1600万英镑的股权融资和1400万英镑的债务融资。
公司目前专注于在2019年第三季度完成LIGHT余下加速部件的生产, 并在2020年底治疗第一名患者。

2018

2018年我们完成并宣布了3700万英镑的股权投资。
LIGHT系统实现生产52MeV能量的质子束, 足以治疗浅表肿瘤。
英国科技设施委员会Daresbury实验室的准备工作启动, 一切按照2020年底治疗首个患者为目标进行计划。

2017

在2017年, 我们完成并宣布了3320万英镑的融资, 包括1680万的股权投资和水睦衡公司1640万英镑的独家分销协议, 该协议将独家授权水睦衡公司在中国澳门台湾香港和韩国销售LIGHT系统。
我们成功完成了LIGHT系统最关键三大部件：侧耦合漂移管直线加速器（SCDTL）与射频四极（RFQ）和质子源的集成与测试。
与英国科技设施委员会达成协议, 在STFC科技园Daresbury实验室建立LIGHT系统的组装测试中心。

2016

在伦敦与日内瓦任命关键高管与董事会成员。
LIGHT系统实现重要技术突破, 成功的完成了质子源与射频四极（RFQ）的集成组装和其他其他加速部件的高能量调试。
与合作伙伴Thales完成了生产优化测试。
通过配售和公开发售筹集了1340万英镑的总收益。
获取哈雷街中心的规划许可
在英国, 美国, 欧洲, 亚洲与中东地区与潜在客户进行市场协商。

2015

成功从The Howard de Walden Estate获取50年的哈雷街中心租约, 第一套LIGHT系统将落户于该中心。
技术开发取得进展
出售非核心资产

2014

与ScandiNova, VDL和东芝达成供应协议

2013

通过并购ADAM SA公司, Advanced Oncotherapy的商业活动逐步发生变化。
完成执行与非执行董事以及医疗顾问委员会成员的任命
获取了LIGHT系统供应保证意向书

2012

公司从CareCapital改名为Advanced oncotherapy, 以反映房地产业务的剥离和公司的战略调整, 旨在发展癌症诊断与治疗领域业务。这为当今的Advanced Oncotherapy发展奠定了基础。

2008

世界上体积最大, 功能最强的粒子加速器大型强子对撞机（LHC）启动。参与该项目的ADAM的科学家；未来ADAM的董事长是该项目的主要研发与管理负责人。

2007

医用质子直线加速LIGHT系统的前身在ADAM团队Alburto Colussi和Ugo Almaldi教授带领下完成设计与制造。

2006

Advanced Oncotherapy前身CareCapital公司在伦敦AIM创业板市场上市。

1994

CareCapital公司成立。主营业务为私有医疗地产的开发与租赁。

BE PART OF THE FUTURE OF CANCER TREATMENT

历史回顾